Healthcare / Drug Manufacturers - Specialty & GenericLSE
$332.00
-1.00 (-0.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $8.3M · quality 84.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$229M
P/E
47.4x
↑EV/EBITDA
1392.0x
↑ROE
4.4%
↑Gross Margin
57.7%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.6%
FCF CAGR
+5.3%
FCF margin
8.5%
FCF / Net income
1.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $89.1M · net income $5.1M · FCF $7.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $89.1M | $89.1M | $74.2M | $70.7M | $71.6M |
| Net Income | $5.1M | $5.1M | $18.5M | $1.2M | $2.0M |
| EBITDA | $16.5M | $16.5M | $13.4M | $11.7M | $10.9M |
| EPS | — | — | 0.30 | 0.02 | 0.03 |
| Gross Margin | 57.7% | 57.7% | 55.6% | 56.8% | 56.8% |
| Operating Margin | 7.0% | 7.0% | 9.5% | 5.7% | 5.8% |
| Net Margin | 5.7% | 5.7% | 24.9% | 1.7% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.20 | 0.08 | 0.14 |
| Current Ratio | 1.61 | 1.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.6M | $7.6M | $8.3M | $8.4M | $6.5M |
| Returns | |||||
| ROE | 4.4% | 4.4% | 16.3% | 1.5% | 2.5% |
| Valuation | |||||
| P/E | 47.43 | 47.43 | 819.40 | 8500.00 | 6875.00 |
| EV/EBITDA | 1391.97 | 1391.97 | 1133.40 | 880.65 | 1226.28 |
| P/B | 200.13 | 200.13 | 133.57 | 132.70 | 169.36 |
| Growth & Yield | |||||
| Revenue Growth | 20.0% | 20.0% | 4.9% | -1.2% | — |
| EPS Growth | — | — | 1395.0% | -37.5% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.30 → n/d
Residual
+11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.